BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE is a prestigious journal published by SPRINGER, dedicated to advancing knowledge in the fields of biochemistry, genetics, molecular biology, and medicine. Established in 1956 and continuing to be relevant through to 2024, this journal provides a vital platform for researchers to publish original findings and significant reviews that contribute to these essential disciplines. With an ISSN of 0007-4888 and an E-ISSN of 1573-8221, it enjoys a respectable standing in the academic community, currently positioned in the Q3 quartile of both Biochemistry, Genetics and Molecular Biology, and Medicine categories for 2023. Despite its traditional subscription model, the journal reaches a wide audience of professionals, students, and researchers, who benefit from timely access to impactful research and experimental studies. By fostering a rich dialogue in experimental biology and medicine, this journal plays an important role in shaping ongoing research and understanding of complex biological systems.

Current Medical Science is a prominent academic journal dedicated to advancing knowledge in the fields of Medicine, Biochemistry, and Genetics. Published by SPRINGER with an ISSN of 2096-5230 and E-ISSN 2523-899X, this journal is based in China and serves as a vital resource for researchers, professionals, and students alike. With a focus on innovative research and emerging trends, Current Medical Science has established itself with an impactful presence, operating under Open Access guidelines to ensure wide dissemination of scientific findings. The journal's recognition is underscored by its impressive Scopus rankings, including a Q3 quartile placement in Biochemistry and Genetics as of 2023. It is noteworthy that the journal spans converged years from 2018 to 2024, providing a comprehensive platform for scholarly discussions and developments that drive the evolution of medical science. As it continues to publish influential research, Current Medical Science plays an essential role in bridging the gap between laboratory science and clinical application.

Future Science OA is an esteemed open-access journal published by FUTURE SCI LTD, dedicated to advancing knowledge in the fields of biotechnology and medicine. Established in 2015, this journal has rapidly gained recognition within the scientific community, evidenced by its impressive ranking in both General Medicine (Rank #100/636, 84th percentile) and Biotechnology (Rank #145/311, 53rd percentile) as per Scopus metrics. With a Q2 category quartile in both fields as of 2023, Future Science OA provides a vital platform for researchers, professionals, and students to share groundbreaking research and innovative ideas. Notably, being an open-access journal allows for a wider dissemination of knowledge, ensuring equal access to high-quality research for practitioners and scholars alike. Based in the United Kingdom, Future Science OA is committed to fostering collaboration and dialogue within the scientific community, making it a cornerstone resource for advancing the future of the life sciences.

Journal of Translational Medicine, published by BMC in the United Kingdom, stands at the forefront of biomedical research, bridging the gap between laboratory discoveries and clinical applications. Established in 2003 as an Open Access journal, it has garnered significant recognition, achieving a Q1 quartile ranking in both Biochemistry, Genetics and Molecular Biology and Medicine categories as of 2023. With an impressive Scopus rank of 38 out of 636 in General Medicine and 33 out of 221 in General Biochemistry, Genetics and Molecular Biology, the journal is committed to disseminating high-quality, peer-reviewed research that impacts healthcare and informs clinical practices. By facilitating free access to groundbreaking studies, the Journal of Translational Medicine aims to enhance collaboration among researchers, professionals, and students in the scientific community, fostering advancements in translational research well into the future.

EXPERIMENTAL BIOLOGY AND MEDICINE is a distinguished open-access journal published by FRONTIERS MEDIA SA, specializing in the interdisciplinary fields of biochemistry, genetics, and medicine. With an ISSN of 1535-3702 and an E-ISSN of 1535-3699, this journal presents a robust platform for cutting-edge research and innovative clinical studies. Since its inception in 1996, it has evolved to feature a broad scope that caters to the evolving needs of researchers, professionals, and students, ensuring a dynamic dissemination of knowledge in biological and medical sciences. In 2023, the journal achieved a notable Q2 ranking in both Biochemistry, Genetics and Molecular Biology and Medicine categories, reflecting its strong impact and relevance within the academic community, as supported by its Scopus rank of #59 out of 221 in general biochemistry and genetics, placing it in the 73rd percentile. By offering open access options, EXPERIMENTAL BIOLOGY AND MEDICINE aims to maximize the reach and visibility of research findings, fostering collaboration and knowledge sharing across global audiences. Researchers are encouraged to contribute to this vital resource as it continues to advance the understanding of biological mechanisms and therapeutic approaches crucial for modern medicine.

Advances in Medical Sciences is a peer-reviewed journal published by Elsevier Urban & Partner Sp. z o.o., dedicated to fostering advancements in the field of medicine and healthcare. Established in 2006, this esteemed journal has become a vital resource for researchers, professionals, and students alike, ranking in the Q2 category for Medicine (Miscellaneous) in 2023 and achieving an impressive 84th percentile in the Scopus rankings for General Medicine, placing it at 99 out of 636 journals. With a focus on publishing high-quality research and comprehensive reviews, this journal serves as a platform for disseminating innovative findings that push the boundaries of medical science. Although open access options are not currently available, the journal's rigorous standards ensure that every published article contributes significantly to the global medical community and promotes the understanding of contemporary medical challenges. Located in Wroclaw, Poland, the journal continues to engage a wide readership, driving forward the dialogue in various facets of medical research.

Biomolecules and Biomedicine is a pioneering open-access journal dedicated to advancing the fields of molecular biology and biomedical sciences, published by the Association of Basic Medical Science Federation Bosnia & Herzegovina in Sarajevo. With the ISSN 2831-0896 and the E-ISSN 2831-090X, this journal aims to facilitate the dissemination of high-quality research from 2023 onwards, inviting submissions that provide innovative insights and findings across various facets of medicine and biological sciences. Positioned within the General Medicine and Biochemistry, Genetics and Molecular Biology categories, it currently holds rankings of 332 out of 636 and 173 out of 221 respectively, highlighting its emerging influence in these fields. As an open-access journal, it ensures that all published research is freely accessible to a global audience, fostering collaboration and knowledge exchange among researchers, professionals, and students alike. With a commitment to enhancing scientific discourse and promoting cutting-edge research, Biomolecules and Biomedicine is poised to become a vital resource for those dedicated to unraveling the complexities of biomolecules and their roles in health and disease.

FASEB BioAdvances, published by WILEY, is an esteemed open-access journal dedicated to advancing the fields of biochemistry, molecular biology, and physiology. Since its inception in 2019, the journal has rapidly established a significant presence within the academic community, boasting an impressive impact factor reflective of its Q2 and Q3 standings across various categories, including Biochemistry, Genetics and Molecular Biology, Cancer Research, Molecular Medicine, and Physiology. The journal aims to disseminate high-quality research and innovative findings to enhance the understanding of biological processes, making it a vital resource for researchers, professionals, and students alike. With its commitment to open access, FASEB BioAdvances ensures that groundbreaking research is available to a global audience, facilitating collaboration and exploration in these rapidly evolving scientific domains.

The BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, published by the ASSOC BRAS DIVULG CIENTIFICA, serves as a vital platform for the dissemination of cutting-edge research in the fields of medicine and biological sciences. With an ISSN of 0100-879X and E-ISSN 1414-431X, this Open Access journal has been championing free access to vital scientific knowledge since 1997. It is indexed in Scopus with notable rankings across various disciplines, including a rank of #131 in General Medicine (79th percentile) and #20 in Pharmacology, Toxicology, and Pharmaceutics (75th percentile). Covering a broad scope of topics, the journal primarily focuses on areas such as biochemistry, biophysics, immunology, neuroscience, and physiology, with a commendable categorization of Q2 and Q3 quartiles for several relevant fields in 2023. Through its commitment to high-quality research and robust peer review processes, the journal not only consolidates its reputation within the academic community but also significantly contributes to the enhancement of scientific knowledge and innovation in Brazil and beyond. Researchers, professionals, and students will find an invaluable resource in this journal, which is pivotal for those looking to stay abreast of the latest developments in medical and biological research.

IN VIVO is a prestigious academic journal published by the International Institute of Anticancer Research, dedicated to advancing the fields of biochemistry, genetics, molecular biology, cancer research, and pharmacology. With its ISSN 0258-851X and E-ISSN 1791-7549, this journal has been a key contributor to innovative research since its inception in 1987, providing a crucial platform for the dissemination of significant findings in its scope. With an impressive impact reflected in its quartile rankings (Q2 in Biochemistry, Genetics and Molecular Biology and Medicine; Q3 in Cancer Research and Pharmacology), IN VIVO reaches a global audience comprising researchers, health professionals, and students. Although it operates on a subscription basis, the journal’s commitment to scientific excellence and rigorous peer review ensures that all published works maintain high quality and relevance. Notably positioned in Scopus ranks within the 36th to 59th percentiles across various categories, IN VIVO continues to be a vital resource for cutting-edge research and developments, solidifying its importance within the scientific community.